Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment

Matsumura,; Moriyama,; Tanaka, M.; Okubo,; Arakawa,

doi:10.1046/j.1365-2893.2000.00235.x

Cited by 85 publications

(79 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Matsumura et al [9] found a greater rate of progression of fibrosis in patients who received blood transfusions at 30 or more years of age. MartinotPegnoux [6] reported an independent relation, based on multivariate analysis, of a more advanced age at Figure 1.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Grading and staging of chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors

Silva¹,

Coelho²,

Nishimura³

et al. 2002

Journal of Hepatology

View full text Add to dashboard Cite

Progression of chronic hepatitis C is known to be associated with some factors, but influence of HCV genotypes is still controversial. Association between HCV genotypes and other risk factors was examined to determine which factors are associated with progression of infection. One hundred consecutive anti-HCV positive volunteer blood donors were evaluated for several risk factors, examined for HCV genotypes, and submitted to hepatic biopsy and biochemical exams.HCV genotyping were carried out in 89 patients and hepatic biopsy in 78. Transmission routes were found to be illicit intravenous drug use (26%), Gluconergan® use in a non-safe manner (48%) and blood transfusion (15%). HCV genotype was 1 in 45%, 3 in 40%, and it was not associated with the stage of fibrosis or with inflammatory activity. There was no significant association of factors related to infection, chronic alcohol use, or duration of illness, with progression of the lesion. There was a significant association of aminotransferase levels and the fibrosis stage. Univariate analysis showed that the age at contamination, patient's age, GT-gamma, and aminotransferase levels over three times the upper normal limits, were associated with fibrosis stages 2 to 4. Multivariate analysis detected age (odds ratio=1.19), and GT-gamma (odds ratio=2.02) as independent factors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The importance of characterizing the HCV genotype is due to its potential association with variations in the evolution of hepatic disease, which is not totally clarified [6,8,9]; moreover the HCV genotype is a strong predictor of sustained response to therapy [6,8].…”

mentioning

confidence: 99%

Grading and staging of chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors

Silva¹,

Coelho²,

Nishimura³

et al. 2002

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…However, the genotype of patients in this registry differs from general Japanese population. The majority (70-80%) of Japanese CH patients are genotype 1, [28][29][30] compared to 56% of CH patients in this study. In our study, most genotype 2 or 3 patients had high viral RNA levels (CH: 91%, comp-LC: 85%).…”

Section: Discussionmentioning

confidence: 66%

Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database

Akutagawa

Kawasaki

et al. 2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Economic evaluation of drugs is used in decision-making on medical care and public policy. Recently, real-world data (RWD) have been used in the analysis. In this study, we discuss the risk and benefits of using RWD for economic evaluation. We conducted a cost-outcome description with RWD from a nationwide registry providing information on hepatitis treatment in Japan and estimated the utility of the analysis. We evaluated the cost-outcome description of peginterferon plus ribavirin (PEG-IFN-α2b RBV) treatment in hepatitis C virus (HCV)-infected patients. Simulations were based on a Markov model. The cohorts were set using data from the registry and we assumed a societal perspective for the calculation of costs. The dose and drug cost were chosen based on the Japanese Guidelines for the Management of Hepatitis C Virus Infection or package inserts. Model details and parameters were as described in previous studies. The simulations were performed for a period of 10 years with no discount rate. We estimated 2.5 million JPY per Quality Adjusted Life Year (QALY) in 48-week PEG-IFN-α2b RBV treatment for a period of 10 years. The results of this study are in agreement with previous HCV treatment economic evaluation studies in Japan. We analyzed the statistics of the HCV-infected patients at each disease stage using the data in our registry and calculated the costs. The results of this study more closely reflect a real-world clinical situation compared to the widely used randomized clinical trial method, which estimates clinical trial results and scenarios.

show abstract

“…It has been reported that in chronic liver disease, changes in the platelet count correlate with the degree of fibrosis in liver histology (31)(32)(33). As a result, the platelet count is regarded as a marker for fibrosis.…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection

Takata

Kuromatsu²,

Ando³

et al. 2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. In recent years, the number of elderly patients with hepatocellular carcinoma (HCC) has been increasing. The aim of this study was to compare the liver function and the background factors of HCC patients with hepatitis C virus (HCV) infection by generation and to examine the characteristics of this disease in the elderly. A total of 1096 patients (776 men and 320 women) diagnosed with HCVrelated HCC at our institution from 1995 to 2006 were divided into 4 groups as follows: D group, 75 years of age or older; C group, 65-74 years of age; B group, 55-64 years of age; A group, 54 years of age or younger, and the liver function and other clinical characteristics were compared among these 4 groups. The average age at initial diagnosis of HCVrelated HCC was 66.9 years of age. The A, B, C and D groups were comprised of 87, 363, 514 and 132 patients, respectively. The rate of Child-Pugh class A patients in the D group was significantly higher than that of the other groups (P<0.05). The average levels of ALT, TB and PT-INR in the D group were significantly lower than the levels in the other groups (P<0.05). The average Alb level in the D group was significantly higher than that in the other groups (P<0.05). In conclusion, we found that HCV-related HCC in the elderly occurred against a background of chronic liver disease with mild inflammation and fibrosis.

show abstract

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment

Cited by 85 publications

References 26 publications

Grading and staging of chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors

Grading and staging of chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors

Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database

HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection

Contact Info

Product

Resources

About